Ask AI
PARPi and TKI Adherence in Breast Cancer

CE / CME

Oral Therapy Adherence: PARP Inhibitors, TKIs, and PIK3/AKT/mTOR Inhibitors

Nurse Practitioners/Nurses: 0.50 Nursing contact hours, includes 0.50 hour of pharmacotherapy credit

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Pharmacists: 0.50 contact hour (0.05 CEUs)

Released: June 16, 2025

Expiration: December 15, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following strategies would be most effective in helping your patient improve adherence to her prescribed therapy?

2.

Which of the following adverse events commonly associated with the addition of capivasertib to endocrine therapy would be important to discuss with your patient with HR-positive metastatic breast cancer who is considering new treatment alternatives?

3.

Your patient with triple-negative breast cancer and a gBRCA1 pathogenic variant will be initiating adjuvant olaparib. Given the potential toxicity, which of the following supportive medications should your patient have available?